<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Addiction</journal-id><journal-id journal-id-type="iso-abbrev">Addiction</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Addiction (Abingdon, England)</journal-title></journal-title-group><issn pub-type="ppub">0965-2140</issn><issn pub-type="epub">1360-0443</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10184496</article-id><article-id pub-id-type="pmcid-ver">PMC10184496.1</article-id><article-id pub-id-type="pmcaid">10184496</article-id><article-id pub-id-type="pmcaiid">10184496</article-id><article-id pub-id-type="manuscript-id">NIHMS1887712</article-id><article-id pub-id-type="pmid">35315173</article-id><article-id pub-id-type="doi">10.1111/add.15878</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1887712</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1887712</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Changes in Predicted Opioid Overdose Risk Over Time in A State Medicaid Program: A Group-Based Trajectory Modeling Analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Guo</surname><given-names initials="J">Jingchuan</given-names></name><degrees>MD PhD</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gellad</surname><given-names initials="WF">Walid F.</given-names></name><degrees>MD MPH</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A4" ref-type="aff">4</xref><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="Q">Qingnan</given-names></name><degrees>MS</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Weiss</surname><given-names initials="JC">Jeremy C.</given-names></name><degrees>MD PhD</degrees><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Donohue</surname><given-names initials="JM">Julie M.</given-names></name><degrees>PhD</degrees><xref rid="A7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cochran</surname><given-names initials="G">Gerald</given-names></name><degrees>PhD</degrees><xref rid="A8" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gordon</surname><given-names initials="AJ">Adam J.</given-names></name><degrees>MD MPH</degrees><xref rid="A8" ref-type="aff">8</xref><xref rid="A9" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Malone</surname><given-names initials="DC">Daniel C.</given-names></name><degrees>PhD</degrees><xref rid="A10" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kwoh</surname><given-names initials="CK">C. Kent</given-names></name><degrees>MD</degrees><xref rid="A11" ref-type="aff">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kuza</surname><given-names initials="CC">Courtney C.</given-names></name><degrees>PhD MPH</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wilson</surname><given-names initials="DL">Debbie L.</given-names></name><degrees>PhD</degrees><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lo-Ciganic</surname><given-names initials="WH">Wei-Hsuan</given-names></name><degrees>PhD</degrees><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib></contrib-group><aff id="A1"><label>1</label>Center for Pharmaceutical Policy and Prescribing, University of Pittsburgh, Pittsburgh, PA</aff><aff id="A2"><label>2</label>Department of Pharmaceutical Outcomes &amp; Policy, College of Pharmacy, University of Florida, Gainesville, FL</aff><aff id="A3"><label>3</label>Center for Drug Evaluation and Safety (CoDES), College of Pharmacy, University of Florida, Gainesville, FL</aff><aff id="A4"><label>4</label>Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA</aff><aff id="A5"><label>5</label>Center for Health Equity Research Promotion, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA</aff><aff id="A6"><label>6</label>Carnegie Mellon University, Heinz College, Pittsburgh, PA</aff><aff id="A7"><label>7</label>Department of Health Policy and Management, University of Pittsburgh, Pittsburgh, PA</aff><aff id="A8"><label>8</label>Program for Addiction Research, Clinical Care, Knowledge, and Advocacy, Division of Epidemiology, Department of Internal Medicine, University of Utah, Salt Lake City, UT</aff><aff id="A9"><label>9</label>Informatics, Decision-Enhancement, and Analytic Sciences Center, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT</aff><aff id="A10"><label>10</label>Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT</aff><aff id="A11"><label>11</label>Division of Rheumatology, Department of Medicine, and the University of Arizona Arthritis Center, University of Arizona, Tucson, Arizona, USA</aff><author-notes><fn fn-type="con" id="FN1"><p id="P1">Author contributions:</p><p id="P2"><bold>Jingchuan Guo</bold>: Conceptualization, formal analysis, investigation, methodology, visualization, and writing &#8211; original draft. <bold>Walid F. Gellad</bold>: Conceptualization, investigation, methodology, funding acquisition, supervision, resources, and writing &#8211; review &amp; editing. <bold>Qingnan Yang</bold>: Data curation, methodology, project administration, and writing &#8211; review &amp; editing. <bold>Jeremy C. Weiss</bold>: Investigation, methodology, and writing &#8211; review &amp; editing. <bold>Julie M. Donohue:</bold> Investigation, methodology, and writing &#8211; review &amp; editing<bold>. Gerald Cochran:</bold> Investigation, methodology, and writing &#8211; review &amp; editing<bold>. Adam J. Gordon:</bold> Investigation, methodology, and writing &#8211; review &amp; editing<bold>. Daniel C. Malone:</bold> Investigation, methodology, and writing &#8211; review &amp; editing. <bold>C. Kent Kwoh:</bold> Investigation, methodology, and writing &#8211; review &amp; editing<bold>. Courtney C. Kuza:</bold> Investigation, methodology, project administration, and writing &#8211; review &amp; editing<bold>. Debbie L. Wilson:</bold> Investigation, methodology, project administration, and writing &#8211; review &amp; editing<bold>. Wei-Hsuan Lo-Ciganic:</bold> Conceptualization, investigation, methodology, supervision, and writing &#8211; review &amp; editing.</p></fn><corresp id="CR1"><bold>Corresponding author:</bold> Wei-Hsuan Lo-Ciganic, PhD, Assistant Professor, Department of Pharmaceutical Outcomes &amp; Policy, College of Pharmacy, HPNP 3338, 1225 Center Drive, Gainesville, FL 32610, Phone +1-352-273-6255, <email>wlociganic@cop.ufl.edu</email></corresp><fn fn-type="COI-statement" id="FN2"><p id="P36">Disclosures/Conflict of interests</p><p id="P37">Dr. Lo-Ciganic has received grant funding from Merck, Sharp &amp; Dohme and Bristol Myers Squibb. Dr. Kwoh has received grant funding from AbbVie and EMD Serono. Dr. Kwoh also serves as a consultant for EMD Serono. All these conflicts of interest are unrelated to this project.</p></fn></author-notes><pub-date pub-type="ppub"><month>8</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>03</day><month>4</month><year>2022</year></pub-date><volume>117</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">435751</issue-id><fpage>2254</fpage><lpage>2263</lpage><pub-history><event event-type="nihms-submitted"><date><day>23</day><month>04</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>08</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>01</day><month>08</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-15 11:25:31.053"><day>15</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1887712.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background and Aims:</title><p id="P3">The time lag encountered when accessing health care data is one major barrier to implementing opioid overdose prediction measures in practice. Little is known regarding how one&#8217;s opioid overdose risk changes over time. We aimed to identify longitudinal patterns of individual predicted overdose risks among Medicaid beneficiaries after initiation of opioid prescriptions.</p></sec><sec id="S2"><title>Design:</title><p id="P4">A retrospective cohort study.</p></sec><sec id="S3"><title>Setting:</title><p id="P5">Pennsylvania, USA.</p></sec><sec id="S4"><title>Participants:</title><p id="P6">Pennsylvania Medicaid beneficiaries aged 18 to 64 years who initiated opioid prescriptions between July 2017 and September 2018 (318,585 eligible beneficiaries (mean age=39&#177;12 years, female=66%, White=62% and Black=25%),</p></sec><sec id="S5"><title>Measurements:</title><p id="P7">We first applied a previously developed and validated machine-learning algorithm to obtain risk scores for opioid overdose emergency room or hospital visits in 3-month intervals for each beneficiary who initiated opioid therapy, until disenrollment from Medicaid, death, or the end of observation (December 2018). We performed group-based trajectory modeling to identify trajectories of these predicted overdose risk scores over time.</p></sec><sec id="S6"><title>Findings:</title><p id="P8">Among eligible beneficiaries, 0.61% had &#8805;1 occurrences of opioid overdose in a median follow-up of 15 months. We identified five unique opioid overdose risk trajectories: three trajectories (accounting for 92% of the cohort) had consistent overdose risk over time including consistent-low risk (63%), consistent-medium risk (25%), and consistent-high risk (4%) groups; another two trajectories (accounting for 8%) had overdose risks that substantially changed over time, including a group that transitioned from high to medium risk (3%) and another group that increased from medium to high risk over time (5%).</p></sec><sec id="S7"><title>Conclusions:</title><p id="P9">Over 90% of Medicaid beneficiaries in Pennsylvania USA with one or more opioid prescriptions had consistent, predicted opioid overdose risks over 15 months. Applying opioid prediction algorithms developed from historical data may not be a major barrier to implementation in practice for the large majority of individuals.</p></sec></abstract><kwd-group><kwd>Opioid overdose</kwd><kwd>risk prediction</kwd><kwd>group-based trajectory models</kwd><kwd>Medicaid</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>